Effect of short-term col-chicine treatment on endothelial function in patients with coronary artery disease.

Int J Cardiol. 2019 Jan 15. pii: S0167-5273(18)34723-5. doi: 10.1016/j.ijcard.2019.01.054. [Epub ahead of print]

Effect of short-term col-chicine treatment on endothelial function in patients with coronary artery disease.

Kajikawa M1, Higashi Y2, Tomiyama H3, Maruhashi T4, Kurisu S4, Kihara Y4, Mutoh A5, Ueda SI6.

Author information

6
Department of Clinical Pharmacology and Therapeutics, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan. Electronic address: blessyou@med.u-ryukyu.ac.jp.

Abstract

BACKGROUND:

Inflammation is associated with endothelial dysfunction and plays an important role in the pathogenesis and development of cardiovascular diseases. It has been shown that col-chicine, an anti-inflammatory drug, improves the cardiovascular outcome in patients with cardiovascular disease. The purpose of this study was to evaluate the short-term effect of low-dose col-chicine on endothelial function in patients with coronary artery disease (CAD).

METHODS:

This was a double-blind, randomized, placebo-controlled, crossover-within-subject clinical trial. A total of 28 patients with CAD received low-dose col-chicine (0.5 mg/day) or a placebo for 7 days with a washout period of at least 14 days. Flow-mediated vasodilation (FMD) and serum concentrations of high-sensitivity C-reactive protein (hs-CRP) were measured after the 7-day treatment with col-chicine or the placebo.

RESULTS:

The serum concentration of hs-CRP was significantly decreased after administration of col-chicine compared with that after administration of the placebo [median (interquartile range): 0.04 (0.02-0.08) mg/dL vs. 0.07 (0.04-0.11) mg/dL, P = 0.003], while there was no significant difference in FMD between the treatments [median (interquartile range): 3.1% (1.5-5.3%) vs. 3.3% (1.9-5.2%), P = 0.384]. Col-chicine, however, significantly improved FMD in coronary artery disease patients with white blood cell (WBC) counts of ≥7500 WBC/mm3[median (interquartile range): 3.3% (2.1-6.6%) vs. 2.0% (1.4-3.8%), P = 0.043].

CONCLUSIONS:

Administration of low-dose col-chicine did not improve endothelial function in patients with CAD, but exploratory analysis suggested that endothelial function is significantly improved in patients with leukocyte activation.

KEYWORDS:

Atherosclerosis; Cardiovascular disease; Colchicine; Endothelial function

view latest selected scientific publications related to “Endothelial Dysfunction”

LATEST SCIENTIFIC UPDATES

Enhance your patient care with the new office-based vascular function test.

Sign Up for our Webinar Series

Why Should We Measure Endothelial Function?